Post-earnings recap
Reported
Mon, May 12, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
13%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Royalty Pharma's earnings report showed a loss per share of $-0.37, with no revenue figures provided. The lack of guidance and commentary leaves investors without clear direction on future performance. The stock reaction was neutral, indicating that investors may have anticipated these results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.